findmyKOL
Clinical trialNCT00993239CompletedPhase 1Interventional

Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

SponsorTetraLogic PharmaceuticalsEnrollment50Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Roswell Park Cancer Institute

    Buffalo, New York, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, United States

  • University of Pennsylvania Abramson Cancer Center

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Birinapant
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2009
Primary completion
31 Aug 2012
Completion
31 Mar 2013
Last update posted
3 Mar 2016
Registered enrollment
50
Registry id
NCT00993239

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.